Yüklüyor......
First-in-Class CDK4/6 Inhibitor Palbociclib Could Usher in a New Wave of Combination Therapies for HR+, HER2− Breast Cancer
Women with hormone receptor–positive, human epidermal growth factor receptor 2− negative breast cancer—the most common subtype—have new options as palbociclib and similar drugs debut. This article outlines the rationale and evidence for their use.
Kaydedildi:
| Yayımlandı: | P T |
|---|---|
| Yazar: | |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
MediMedia USA, Inc.
2015
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4517534/ https://ncbi.nlm.nih.gov/pubmed/26236140 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|